Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:

Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.
Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.
Current Opinion articles that place interesting areas in perspective.
Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.
Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.
Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

Editor (Adis International Limited, Auckland, New Zealand):
Martin Chopra
Honorary Member
Gabriel N. Hortobagyi, Houston, TX, USA
Consulting Editor
Jean-François Morère, Hôpital Avicenne, Paris-Nord, France
Editorial Advisory Board
J.O. Armitage, University of Nebraska Medical Center, Omaha, NE, USA
J.R. Berenson, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA
J.-Y. Blay, University Claude Bernard Lyon I, Lyon, France
T. Buchler, Charles University and Thomayer Hosptial, Prague, Czech Republic
A.-L. Cheng, National Taiwan University, Taipei, Taiwan
F. Ciardiello, Second University of Naples, Naples, Italy
J. Desai, The Royal Melbourne Hospital, Melbourne, VIC, Australia
S. Faivre, Beaujon University Hospital, Clichy, France
G. Giaccone, Georgetown University, Washington, DC, USA
P. Grivas, University of Washington, Seattle, WA, USA
V.C. Jordan, MD Anderson, Houston, Texas, USA
J.M. Kirkwood, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
H.-J. Lenz, University of Southern California, Los Angeles, CA, USA
R. Liang, The University of Hong Kong, Hong Kong
T. Macarulla, Vall d'Hebron University Hospital, Barcelona, Spain
W.P. McGuire, Virginia Commonwealth University, Richmond, VA, USA
M.J. McKeage, University of Auckland, Auckland, New Zealand
A. Mita, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
M. Mita, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
A.G. Papavassiliou, National and Kapodistrian University of Athens, Athens, Greece
S. Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
C.C. Porta, IRCCS San Matteo University Hospital Foundation, Pavia, Italy
T. J. Price, The Queen Elizabeth Hospital, Adelaide, SA, Australia
S. Qin, Chinese Society of Clinical Oncology, Nanjing, China
E. Raymond, Groupe Hospitalier Paris Saint-Joseph, Paris, France
N. Reguart, Hospital Clinic Barcelona, Barcelona, Spain
O. Rixe, Quantum Santa Fe, Santa Fe, NM, USA
H. Rizos, Macquarie University, North Ryde, NSW, Australia
C. Rolfo, University of Maryland, Baltimore, MD, USA
H.-J. Schmoll, Martin-Luther-University Halle-Wittenberg, Halle, Germany

N.A. Shonka, University of Nebraska Medical Center, Omaha, NE, USA
D. Soulières, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, Spain
E. Van Cutsem, University Hospitals Leuven, Leuven, Belgium
J.E-L. Wong, National University of Singapore, Singapore